
-
BlogOn April 13, The Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) recommended pausing the use of Johnson and Johnson’s Janssen vaccine out of an abundance of caution after reports of blood clotting in 6 individuals who recentlyFDA, CDC Recommend J&J Vaccine Pause
-
Blog
FDA, CDC Recommend J&J Vaccine Pause
On April 13, The Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) recommended pausing the use of Johnson and Johnson’s Janssen vaccine out of an abundance of caution after reports of blood clotting in 6 individuals who recently received the vaccine. The CDC and FDA emphasized the recommended pause would enable them to review the cases, ensure the healthcare community was aware of how to recognize, treat, and report instances of the rare clotting condition, and make additional recommendations on eligibility for the Johnson and Johnson vaccine if needed.
The CDC and FDA are reviewing 6 cases in which women suffered a rare and severe type of blood clot in the weeks after receiving the Johnson and Johnson vaccine. The cases of cerebral venous sinus thrombosis (CVST) occurred among women between the ages of 18 and 48. These cases have not yet been directly linked to the vaccine and make up an extremely small portion of doses administered, as almost 7 million Americans have received a J&J vaccine.
Information for Individual County Residents
FDA officials are encouraging people who received J&J in last couple weeks to monitor symptoms of blood clotting, which include severe headaches, abdominal pain, leg pain, and/or shortness of breath. These symptoms differ from typical symptoms people generally have after being vaccinated, which include (but are not limited to) pain the arm where the shot was administered, fatigue, and fever.
Officials from both CDC and FDA emphasized that people who have received a vaccine from either Pfizer or Moderna , or have received a Johnson and Johnson vaccine more than three weeks ago should not be concerned. No clotting incidences have been identified in the nearly 185 million people combined that have received the Pfizer Moderna vaccines. Those individuals who are experiencing symptoms of blood clotting after being vaccinated by the Johnson and Johnson vaccine should contact their medical provider and disclose that they were recently vaccinated.
Information for County Health Officials
Local officials should work to reschedule appointments with patients who had appointments to receive the Johnson and Johnson vaccines and redirect them to Pfizer or Moderna vaccine appointments, until federal authorities indicate that Johnson and Johnson vaccinations are safe to continue.
On April 13, the White House released a statement indicating that the announcement regarding the Johnson and Johnson vaccine will not impact the supply vaccine doses to local authorities. The federal government intends to make 28 million doses of Pfizer and Moderna available to states beginning the week of April 12 to account for the potential impact, a 3 million dose increase from the previous week.
CDC and FDA experts are projecting that the pause should only last for a matter of days, though there was no specific timeline given. The CDC’s Advisory Committee on Immunization Practices (ACIP) held an emergency meeting on at 1:30 p.m. on April 14 to review these cases, assess their significance, and determine next steps. Following this event, the FDA and CDC will examine the committee’s findings and communicate their results with healthcare providers.
In the meantime, healthcare providers should familiarize themselves with the rare clotting condition and screen anyone coming in with symptoms by asking if they were recently vaccinated, in an effort to best diagnose, treat, and report the incidence.
Counties, which operate and support over 1,900 local public health departments, nearly 1,000 public hospitals and critical access clinics, more than 800 long-term care facilities, as well as supporting over 1,300 community health centers, have been leading the on-the-ground efforts of the nation-wide vaccination campaign. NACo is committed to working with the federal government to deliver clear and fact based information to local governments to assist them in this unprecedented undertaking, and ensure counties can continue to provide safe, responsible care to its citizens.
Additional Resources:
- NACo’s COVID-19 Vaccine Distribution Toolkit
- NACo FAQ: Johnson and Johnson Vaccine Distribution Pause
- NACo Blog: FDA issues an emergency use authorization for a third COVID-19 vaccine, manufacturers ramp up production
On April 13, The Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) recommended pausing the use of Johnson and Johnson’s Janssen2021-04-15Blog2021-04-16
On April 13, The Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) recommended pausing the use of Johnson and Johnson’s Janssen vaccine out of an abundance of caution after reports of blood clotting in 6 individuals who recently received the vaccine. The CDC and FDA emphasized the recommended pause would enable them to review the cases, ensure the healthcare community was aware of how to recognize, treat, and report instances of the rare clotting condition, and make additional recommendations on eligibility for the Johnson and Johnson vaccine if needed.
The CDC and FDA are reviewing 6 cases in which women suffered a rare and severe type of blood clot in the weeks after receiving the Johnson and Johnson vaccine. The cases of cerebral venous sinus thrombosis (CVST) occurred among women between the ages of 18 and 48. These cases have not yet been directly linked to the vaccine and make up an extremely small portion of doses administered, as almost 7 million Americans have received a J&J vaccine.
Information for Individual County Residents
FDA officials are encouraging people who received J&J in last couple weeks to monitor symptoms of blood clotting, which include severe headaches, abdominal pain, leg pain, and/or shortness of breath. These symptoms differ from typical symptoms people generally have after being vaccinated, which include (but are not limited to) pain the arm where the shot was administered, fatigue, and fever.
Officials from both CDC and FDA emphasized that people who have received a vaccine from either Pfizer or Moderna , or have received a Johnson and Johnson vaccine more than three weeks ago should not be concerned. No clotting incidences have been identified in the nearly 185 million people combined that have received the Pfizer Moderna vaccines. Those individuals who are experiencing symptoms of blood clotting after being vaccinated by the Johnson and Johnson vaccine should contact their medical provider and disclose that they were recently vaccinated.
Information for County Health Officials
Local officials should work to reschedule appointments with patients who had appointments to receive the Johnson and Johnson vaccines and redirect them to Pfizer or Moderna vaccine appointments, until federal authorities indicate that Johnson and Johnson vaccinations are safe to continue.
On April 13, the White House released a statement indicating that the announcement regarding the Johnson and Johnson vaccine will not impact the supply vaccine doses to local authorities. The federal government intends to make 28 million doses of Pfizer and Moderna available to states beginning the week of April 12 to account for the potential impact, a 3 million dose increase from the previous week.
CDC and FDA experts are projecting that the pause should only last for a matter of days, though there was no specific timeline given. The CDC’s Advisory Committee on Immunization Practices (ACIP) held an emergency meeting on at 1:30 p.m. on April 14 to review these cases, assess their significance, and determine next steps. Following this event, the FDA and CDC will examine the committee’s findings and communicate their results with healthcare providers.
In the meantime, healthcare providers should familiarize themselves with the rare clotting condition and screen anyone coming in with symptoms by asking if they were recently vaccinated, in an effort to best diagnose, treat, and report the incidence.
Counties, which operate and support over 1,900 local public health departments, nearly 1,000 public hospitals and critical access clinics, more than 800 long-term care facilities, as well as supporting over 1,300 community health centers, have been leading the on-the-ground efforts of the nation-wide vaccination campaign. NACo is committed to working with the federal government to deliver clear and fact based information to local governments to assist them in this unprecedented undertaking, and ensure counties can continue to provide safe, responsible care to its citizens.
Additional Resources:
- NACo’s COVID-19 Vaccine Distribution Toolkit
- NACo FAQ: Johnson and Johnson Vaccine Distribution Pause
- NACo Blog: FDA issues an emergency use authorization for a third COVID-19 vaccine, manufacturers ramp up production

About Blaire Bryant (Full Bio)
Legislative Director – Health | Large Urban County Caucus
More from Blaire Bryant
-
Reports & Toolkits
NACo FAQ: Johnson and Johnson Vaccine Distribution Pause
On April 13, The Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) recommended pausing the use of Johnson and Johnson’s Janssen vaccine out of an abundance of caution after reports of blood clotting in 6 individuals who recently received the vaccine
-
Blog
Biden-Harris administration takes steps to address monkeypox outbreak
On August 4, in response to continued transmission in the U.S. and globally, the U.S. Department of Health and Human Services (HHS) declared the monkeypox virus a Public Health Emergency (PHE). -
Blog
Applications Open for Initiative to Support Rural County Residents with Substance Use Disorders
The United States is experiencing an epidemic of drug overdose deaths. While no corner of the country has gone untouched, the overdose crisis has hit rural America particularly hard. Between 1999 and 2015, overdose deaths increased 325 percent in rural counties. -
Blog
White House to hold Inflation Reduction Act briefings this week
Throughout the week of August 15, the White House will hold a series of four briefings to discuss the Inflation Reduction Act (IRA). -
Blog
Inflation Reduction Act Signed Into Law
On August 16, President Biden signed the Inflation Reduction Act (IRA) into law. -
Blog
NACo’s listening session findings for the White House Hunger Conference
On June 30, the National Association of Counties (NACo) hosted a virtual listening session to inform the White House national strategy to end hunger, increase healthy eating and physical activity and reduce diet related diseases in the United States by 2030. -
Video
Supporting People with Opioid Use Disorders Involved in the Justice System
In this session, attendees will learn evidence-based strategies to prevent and treat opioid use disorders and hear about a new NACo resource to support these efforts.
-
Webinar
Reaching Rural: Advancing Collaborative Solutions
August 31, 2022 , 2:00 pm – 3:00 pmNACo and partners at Bureau of Justice Assistance, CDC and State Justice Institute are excited to announce the new initiative,08312:00 pm<p>NACo and partners at <a href="https://bja.ojp.gov/" target="_blank">Bureau of Justice Assistance</a>, <a href="htt
-
Webinar
The Opioid Response Network: A Free and Localized Resource to Enhance County-Led Efforts
August 31, 2022 , 3:00 pm – 4:00 pmCounties across the nation are on the front lines of the opioid and stimulant crisis providing essential public services. To enhance these efforts, refine approaches, fill gaps and help counties achieve their goals, NACo has partnered with the Opioid Response Network (ORN).08313:00 pm<p>Counties across the nation are on the front lines of the opioid and stimulant crisis providing essential public services.
-
Basic page
The Stepping Up Initiative
In May 2015, NACo and partners at the CSG Justice Center and APA Foundation launched Stepping Up: A National Initiative to Reduce the Number of People with Mental Illnesses in Jails.pagepagepage<h2>Overview</h2>
<blockquote>
<h3>Join the Initiative!</h3> -
Reports & Toolkits
COVID-19 Recovery Clearinghouse
The COVID-19 Recovery Clearinghouse features timely resources for counties, including allocation estimations, examples of county programs using federal coronavirus relief funds, the latest news and more.Reports & Toolkitsdocument03127:15 pmReports & Toolkits<table border="1" cellpadding="1" cellspacing="1" style="width:100%" summary="ad-block no-top-margin no-bullets">
<caption>Jump to Section</caption> -
Basic page
Live Healthy U.S. Counties
The National Association of Counties (NACo) Live Healthy Prescription, Health & Dental Discount Program is a NO-COST program available to all member counties.pagepagepage<h1>With <a id="naco" name="naco">NACo</a>, Saving Feels Better</h1>
-
Reports & Toolkits
Opioid Solutions Center
Through the Opioid Solutions Initiative, NACo empowers local leaders to invest resources in effective treatment, recovery, prevention and other public health practices that save lives and address the underlying causes of substance use disorder.Reports & Toolkitsdocument06063:30 pmReports & Toolkits<table border="1" cellpadding="1" cellspacing="1" style="width:100%" summary="call-out">
<tbody>
<tr>
<td>
Contact
-
Legislative Director – Health | Large Urban County Caucus(202) 942-4246
Related Posts
-
BlogBiden-Harris administration takes steps to address monkeypox outbreakAug. 17, 2022
-
BlogApplications Open for Initiative to Support Rural County Residents with Substance Use DisordersAug. 17, 2022
-
BlogWhite House to hold Inflation Reduction Act briefings this weekAug. 15, 2022
Related Resources
-
VideoSupporting People with Opioid Use Disorders Involved in the Justice SystemJul. 23, 2022
-
VideoCelebrating County Opioid Litigation Wins and Planning for What’s NextJul. 23, 2022
-
VideoONDCP Director Dr. Rahul Gupta Addresses #NACoAnnJul. 22, 2022
Related Events
-
31Aug2022
-
31Aug2022Webinar
The Opioid Response Network: A Free and Localized Resource to Enhance County-Led Efforts
Aug. 31, 2022 , 3:00 pm – 4:00 pm
More From
-
How communities are investing American Rescue Plan funds with the Local Government ARPA Investment Tracker
The Local Government ARPA Investment Tracker, powered by NACo, Brookings Metro and National League of Cities provides a detailed local investment picture of American Rescue Plan Act funding.
Learn More